{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:08:51Z","timestamp":1771232931077,"version":"3.50.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1097\/ftd.0000000000000070","type":"journal-article","created":{"date-parts":[[2014,3,28]],"date-time":"2014-03-28T21:01:36Z","timestamp":1396040496000},"page":"651-655","source":"Crossref","is-referenced-by-count":44,"title":["Effects of Genetic Polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the Steady-State Plasma Concentrations of Aripiprazole and Its Active Metabolite, Dehydroaripiprazole, in Japanese Patients With Schizophrenia"],"prefix":"10.1097","volume":"36","author":[{"given":"Takeshi","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Mihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akifumi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goyo","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Nemoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-14-20210129","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":". Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"R2-14-20210129","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2165\/00003495-200464150-00010","article-title":"Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.","volume":"64","author":"Harrison","year":"2004","journal-title":"Drugs"},{"key":"R3-14-20210129","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.eurpsy.2007.03.002","article-title":". A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients. Schizophrenia Trial of Aripiprazole (STAR) Study.","volume":"22","author":"Kerwin","year":"2007","journal-title":"Eur Psychiatry"},{"key":"R4-14-20210129","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1440-1819.2012.02391.x","article-title":". Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptors and cytochrome P450 2D6 in Japanese patients with schizophrenia.","volume":"66","author":"Nagai","year":"2012","journal-title":"Psychiatry Clin Neurosci"},{"key":"R5-14-20210129","first-page":"1","article-title":". Improvement in antipsychotic-induced hyperprolactinemia with addition of aripiprazole in schizophrenic patients.","volume":"1","author":"Mihara","year":"2011","journal-title":"Clin Neuropsychopharmacol Ther"},{"key":"R6-14-20210129","doi-asserted-by":"crossref","first-page":"612","DOI":"10.2174\/138920007781368908","article-title":"N-dealkylation of arylpiperazine derivatives: disposition and metabolism of the 1-aryl-piperazines formed.","volume":"8","author":"Caccia","year":"2007","journal-title":"Curr Drug Metab"},{"key":"R7-14-20210129","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/15622970701361255","article-title":". Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects.","volume":"9","author":"Kirschbaum","year":"2008","journal-title":"World J Biol Psychiatry"},{"key":"R8-14-20210129","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2133\/dmpk.20.55","article-title":". Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole.","volume":"20","author":"Kubo","year":"2005","journal-title":"Drug Metab Pharmacokinet"},{"key":"R9-14-20210129","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-007-0373-6","article-title":". Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole.","volume":"63","author":"Hendset","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"R10-14-20210129","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1365-2125.2008.03223.x","article-title":". Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients.","volume":"66","author":"Kim","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"R11-14-20210129","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/FTD.0b013e3182031021","article-title":". Effects of the CYP2D610 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.","volume":"33","author":"Suzuki","year":"2011","journal-title":"Ther Drug Monit"},{"key":"R12-14-20210129","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/FTD.0b013e31824a31e6","article-title":". Effects of paroxetine on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.","volume":"34","author":"Nemoto","year":"2012","journal-title":"Ther Drug Monit"},{"key":"R13-14-20210129","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/FTD.0000000000000018","article-title":". Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype.","volume":"36","author":"Hendset","year":"2014","journal-title":"Ther Drug Monit"},{"key":"R14-14-20210129","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00008571-199508000-00005","article-title":". Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.","volume":"5","author":"Steen","year":"1995","journal-title":"Pharmacogenetics"},{"key":"R15-14-20210129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1365-2125.2000.00209.x","article-title":". Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes.","volume":"50","author":"Kubota","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"R16-14-20210129","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0026-895X(25)09721-4","article-title":". Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.","volume":"46","author":"Johansson","year":"1994","journal-title":"Mol Pharmacol"},{"key":"R17-14-20210129","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2174\/138920008784746373","article-title":". Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions.","volume":"9","author":"Urichuk","year":"2008","journal-title":"Curr Drug Metab"},{"key":"R18-14-20210129","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/jcp.0b013e318056f309","article-title":". Pharmacokinetics of aripiprazole and concomitant carbamazepine.","volume":"27","author":"Citrome","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"R19-14-20210129","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/FTD.0b013e3181b6326a","article-title":". Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia.","volume":"31","author":"Nakamura","year":"2009","journal-title":"Ther Drug Monit"},{"key":"R20-14-20210129","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00008571-200112000-00005","article-title":". The genetic determinants of the CYP3A5 polymorphism.","volume":"11","author":"Hustert","year":"2001","journal-title":"Pharmacogenetics"},{"key":"R21-14-20210129","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2009.01.011","article-title":". Aripiprazole brain concentration is altered in P-glycoprotein deficient mice.","volume":"110","author":"Wang","year":"2009","journal-title":"Schizophr Res"},{"key":"R22-14-20210129","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.neuropharm.2010.06.010","article-title":". Pharmacokinetics of acute and sub-acute aripiprazole in P-glycoprotein deficient mice.","volume":"59","author":"Kirschbaum","year":"2010","journal-title":"Neuropharmacology"},{"key":"R23-14-20210129","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2217\/pgs.11.55","article-title":". Relationship between P-glycoprotein and second-generation antipsychotics.","volume":"12","author":"Moons","year":"2011","journal-title":"Pharmacogenomics"},{"key":"R25-14-20210129","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2133\/dmpk.22.358","article-title":". Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism.","volume":"22","author":"Kubo","year":"2007","journal-title":"Drug Metab Pharmacokinet"},{"key":"R26-14-20210129","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jchromb.2005.06.023","article-title":". Development and validation of an LC-MSMS method for the quantitative determination of aripiprazole and its main metabolite, OPC-14857, in human plasma.","volume":"822","author":"Kubo","year":"2005","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R27-14-20210129","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1124\/dmd.108.023242","article-title":". Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57).","volume":"36","author":"Sakuyama","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"R28-14-20210129","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/01.fpc.0000230411.89973.1b","article-title":". CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population.","volume":"16","author":"Mirghani","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"R29-14-20210129","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0009-9120(03)00092-4","article-title":". Detection of the four sequence variations of MDR1 gene using TaqMan MGB probe based real-time PCR and haplotype analysis in healthy Japanese subjects.","volume":"36","author":"Saito","year":"2003","journal-title":"Clin Biochem"},{"key":"R30-14-20210129","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1248\/bpb.26.510","article-title":"Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor.","volume":"26","author":"Usui","year":"2003","journal-title":"Biol Pharm Bull"},{"key":"R31-14-20210129","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1124\/dmd.104.001313","article-title":"2nd, et al.. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism.","volume":"32","author":"Huang","year":"2004","journal-title":"Drug Metab Dispos"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T05:52:58Z","timestamp":1746165178000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201410000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000070","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]}}}